Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Education
Published in: Journal of Cancer Education 2/2020

Open Access 01-04-2020 | NSCLC

Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer

Authors: Dóra Révész, Ellen G. Engelhardt, Johannes J. Tamminga, Franz M. N. H. Schramel, Bregje D. Onwuteaka-Philipsen, Ewoudt M. W. van de Garde, Ewout W. Steyerberg, Henrica C.W. de Vet, Veerle M. H. Coupé

Published in: Journal of Cancer Education | Issue 2/2020

Login to get access

Abstract

Treatment decision-making for patients with incurable non-small cell lung cancer (NSCLC) is complex due to the rapidly increasing number of treatments and discovery of new biomarkers. Decision support systems (DSS) could assist thoracic oncologists (TO) weighing of the pros and cons of treatments in order to arrive at an evidence-based and personalized treatment advice. Our aim is to inventory (1) TO’s needs with regard to DSS in the treatment of incurable (stage IIIB/IV) NSCLC patients, and (2) preferences regarding the development of future tools in this field. We disseminated an online inventory questionnaire among all members of the Section of Oncology within the Society of Physicians in Chest Medicine and Tuberculosis. Telephone interviews were conducted to better contextualize the findings from the questionnaire. In total, 58 TO completed the questionnaire and expressed a need for new DSS. They reported that it is important for tools to include genetic and immune markers, to be sufficiently validated, regularly updated, and time-efficient. Also, future DSS should incorporate multiple treatment options, integrate estimates of toxicity, quality of life and cost-effectiveness of treatments, enhance communication between caregivers and patients, and use IT solutions for a clear interface and continuous updating of tools. With this inventory among Dutch TO, we summarized the need for new DSS to aid treatment decision-making for patients with incurable NSCLC. To meet the expressed needs, substantial additional efforts will be required by DSS developers, above already existing tools.
Literature
1.
2.
3.
4.
Revesz D, Engelhardt EG, Tamminga JJ, Schramel F, Onwuteaka-Philipsen BD, van de Garde EMW et al (2017) Decision support systems for incurable non-small cell lung cancer: a systematic review. BMC Med Inform Decis Mak 17(1):144CrossRef
5.
Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA (2008) A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 3(6):590–598CrossRef
6.
Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2012) Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 7(9):1361–1368CrossRef
7.
Tseng YD, Krishnan MS, Sullivan AJ, Jones JA, Chow E, Balboni TA (2013) How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: a survey-based study. Int J Radiat Oncol Biol Phys 87(3):471–478CrossRef
8.
Chiu N, Chiu L, Lutz S, Zhang N, Lechner B, Pulenzas N, Popovic M, DeAngelis C, Milakovic M, Chow R, Chow E (2015) Incorporation of life expectancy estimates in the treatment of palliative care patients receiving radiotherapy: treatment approaches in light of incomplete prognostic models. Ann Palliat Med 4(3):162–168PubMed
9.
Hallen SA, Hootsmans NA, Blaisdell L, Gutheil CM, Han PK (2015) Physicians’ perceptions of the value of prognostic models: the benefits and risks of prognostic confidence. Health Expect 18(6):2266–2277CrossRef
10.
Engelhardt EG, Pieterse AH, van Duijn-Bakker N, Kroep JR, de Haes HC, Smets EM et al (2015) Breast cancer specialists’ views on and use of risk prediction models in clinical practice: a mixed methods approach. Acta Oncol 54(3):361–367CrossRef
11.
Langton JM, Blanch B, Pesa N, Park JM, Pearson SA (2013) How do medical doctors use a web-based oncology protocol system? A comparison of Australian doctors at different levels of medical training using logfile analysis and an online survey. BMC Med Inform Decis Mak 13:82CrossRef
12.
Bansal P, Osman D, Gan GN, Simon GR, Boumber Y (2016) Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol 6:112PubMedPubMedCentral
13.
Chen JY, Cheng YN, Han L, Wei F, Yu WW, Zhang XW, Cao S, Yu JP (2015) Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biol Med 12(2):126–139PubMedPubMedCentral
14.
Shea M, Costa DB, Rangachari D (2016) Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 10(2):113–129CrossRef
15.
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R (2015) Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 10(1 Suppl 1):S1–S63CrossRef
16.
Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR (2015) Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 21(10):2236–2243CrossRef
17.
Hall RD, Le TM, Haggstrom DE, Gentzler RD (2015) Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res 4(5):515–523PubMedPubMedCentral
18.
Herzberg B, Campo MJ, Gainor JF (2016) Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist
19.
Tan WL, Jain A, Takano A, Newell EW, Iyer NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL, Tan DSW (2016) Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol 17(8):e347–e362CrossRef
20.
21.
Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL, American Society of Clinical Oncology (2015) American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33(23):2563–2577CrossRef
22.
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39CrossRef
23.
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016) NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Cancer Netw 14(3):255–264CrossRef
24.
Downing GJ, Boyle SN, Brinner KM, Osheroff JA (2009) Information management to enable personalized medicine: stakeholder roles in building clinical decision support. BMC Med Inform Decis Mak 9:44CrossRef
25.
Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F (2015) The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today 20(12):1433–1438CrossRef
26.
Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2016
27.
Finlayson SG, Levy M, Reddy S, Rubin DL (2016) Toward rapid learning in cancer treatment selection: an analytical engine for practice-based clinical data. J Biomed Inform 60:104–113CrossRef
Metadata
Title
Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer
Authors
Dóra Révész
Ellen G. Engelhardt
Johannes J. Tamminga
Franz M. N. H. Schramel
Bregje D. Onwuteaka-Philipsen
Ewoudt M. W. van de Garde
Ewout W. Steyerberg
Henrica C.W. de Vet
Veerle M. H. Coupé
Publication date
01-04-2020
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 2/2020
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-019-1471-8

Other articles of this Issue 2/2020

Journal of Cancer Education 2/2020 Go to the issue

OriginalPaper

The Effect of Self-Management Education by the Teach-Back Method on Uncertainty of Patients with Breast Cancer: a Quasi-Experimental Study

OriginalPaper

Assessment of Patients’ Knowledge in Managing Side Effects of Chemotherapy: Case of King Abdul-Aziz University Hospital

OriginalPaper

Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice

OriginalPaper

Evaluation of the St. Jude Cancer Education for Children Program on Cancer Risk Awareness, Attitudes, and Behavioral Intentions Among Fourth-Grade Science Students: Comparisons Between Racially Identifiable/High-Poverty Schools and Racially Diverse/Affluent Schools

OriginalPaper

Managing Pain in People with Cancer—a Systematic Review of the Attitudes and Knowledge of Professionals, Patients, Caregivers and Public

OriginalPaper

Comparison of Quality of Life and Learning Success of Adolescents Surviving Cancer and Their Classmates
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits